Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jun 19:15:1390907.
doi: 10.3389/fimmu.2024.1390907. eCollection 2024.

Research progress of SIRTs activator resveratrol and its derivatives in autoimmune diseases

Xiaolong Yu  1   2   3 , Mingkai Chen  2 , Jiabiao Wu  2 , Ruixiao Song  2   3
Affiliations
Review

Research progress of SIRTs activator resveratrol and its derivatives in autoimmune diseases

Xiaolong Yu et al. Front Immunol. .

Abstract

Autoimmune diseases (AID) have emerged as prominent contributors to disability and mortality worldwide, characterized by intricate pathogenic mechanisms involving genetic, environmental, and autoimmune factors. In response to this challenge, a growing body of research in recent years has delved into genetic modifications, yielding valuable insights into AID prevention and treatment. Sirtuins (SIRTs) constitute a class of NAD-dependent histone deacetylases that orchestrate deacetylation processes, wielding significant regulatory influence over cellular metabolism, oxidative stress, immune response, apoptosis, and aging through epigenetic modifications. Resveratrol, the pioneering activator of the SIRTs family, and its derivatives have captured global scholarly interest. In the context of AID, these compounds hold promise for therapeutic intervention by modulating the SIRTs pathway, impacting immune cell functionality, suppressing the release of inflammatory mediators, and mitigating tissue damage. This review endeavors to explore the potential of resveratrol and its derivatives in AID treatment, elucidating their mechanisms of action and providing a comprehensive analysis of current research advancements and obstacles. Through a thorough examination of existing literature, our objective is to advocate for the utilization of resveratrol and its derivatives in AID treatment while offering crucial insights for the formulation of innovative therapeutic approaches.

Keywords: SIRTs; SIRTs activators; autoimmune diseases; derivative; resveratrol; sirtuins.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
A review of the discovery and development of resveratrol and its derivatives.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Karagianni P, Tzioufas AG. Epigenetic perspectives on systemic autoimmune disease. J Autoimmun. (2019) 104:102315. doi: 10.1016/j.jaut.2019.102315 - DOI - PubMed
    1. Kiriakidou M, Ching CL. Systemic lupus erythematosus. Ann Intern Med. (2020) 172:ITC81–96. doi: 10.7326/AITC202006020 - DOI - PubMed
    1. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet. (2010) 376:1094–108. doi: 10.1016/S0140-6736(10)60826-4 - DOI - PubMed
    1. Bartalena L. Diagnosis and management of Graves disease: a global overview. Nat Rev Endocrinol. (2013) 9:724–34. doi: 10.1038/nrendo.2013.193 - DOI - PubMed
    1. Burn P. Type 1 diabetes. Nat Rev Drug Discov. (2010) 9:187–8. doi: 10.1038/nrd3097 - DOI - PubMed

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This study was funded by Jiangsu Key Laboratory of Immunology and Metabolism (XZSYSKF2020018), Medical Education Collaborative Innovation Fund of Jiangsu University (No.JDYY2023078) and the Changzhou High-Level Medical Talents Training Project (2022CZBJ109).